InMode stock is showing downward pressure. What should traders watch with INMD?Committee Rejects Proposals As Not Attractive EnoughThe committee, formed by InMode's board, evaluated multiple proposals for a potential transaction with help from outside financial and legal advisers. After reviewing the final bids, it concluded that none were adequate or in the best interests of the company and its shareholders, and decided to discontinue the process.InMode said it will continue to review its business and grow ...

InMode Announces Conclusion of Independent Transaction Committee Review [Accessibility Statement] Skip NavigationYOKNEAM, Israel, Feb. 23, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today announced that the independent transaction committee of its Board of Directors (the "Committee") has completed its review of proposals received in connection with a potential transaction.Since its formation, the Committee has con ...

Company Overview - InMode Ltd. is an Israeli-based company specializing in medical aesthetics, providing platforms and technology for both minimally invasive and non-invasive procedures [1] - The company offers 12 platforms that deliver a variety of treatments, including radio-frequency (RF) micro-needling [1] Investment Philosophy - The investment approach emphasizes the importance of compounding, dividend reinvesting, and patient investing through various market conditions to achieve wealth creation [1] - The strategy includes a mix of steady accumulation of high-quality assets along with high-risk/high-reward opportunities and transformative technologies [1] Academic Background - The individual associated with the analysis has over 20 years of teaching experience at the college/university level and holds a PhD from Brunel University [1]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.9 million, up from $97.9 million in Q4 2024, while full-year revenue for 2025 totaled $370.5 million, a 6% decrease compared to 2024 [8][9] - Gross margins for Q4 2025 were 78% on a GAAP basis, down from 79% in Q4 2024, while non-GAAP gross margins were 79% for both Q4 and full year 2025 [9][11] - GAAP diluted earnings per share for Q4 2025 were $0.42, compared to $1.14 in Q4 2024, and $1.43 for the full year 2025, down from $2.25 in 2024 [11][12] Business Line Data and Key Metrics Changes - Revenue from consumables and services increased slightly compared to last year, indicating early signs of stabilization in patient activity [4] - Minimally invasive technology platforms accounted for 76% of total revenues in Q4 2025, while consumables and services represented 22% of revenue, up from 20% in 2024 [9][10] Market Data and Key Metrics Changes - Sales outside the U.S. totaled $48.5 million in Q4 2025, representing 47% of total sales and a 38% increase compared to Q4 2024, driven primarily by Europe [9] - For the full year 2025, sales outside the U.S. accounted for $171.8 million, or 46% of total sales, representing a 15% increase compared to 2024 [9] Company Strategy and Development Direction - The company views 2026 as a stabilization year following a prolonged period of industry softness, with plans to continue innovating and introducing new platforms [4][6] - A specialized sales team has been established for the Envision platform, aimed at increasing penetration and improving sales productivity [5] - The company plans to launch two new platforms in 2026, including a Korean-made Pico laser device and a device combining new Morpheus technology with Erbium YAG laser [6] Management's Comments on Operating Environment and Future Outlook - Management noted that the industry has not yet fully recovered from the global economic slowdown, with demand in North America remaining below historical levels, but there are early signs of stabilization [7] - The CEO mentioned that interest rates starting to come down could positively impact leasing packages for capital equipment purchases [17] Other Important Information - The company returned $127.4 million to shareholders through a disciplined share repurchase program [13] - The board of directors is exploring strategic alternatives to improve company value, having engaged Bank of America for assistance [20] Q&A Session Summary Question: What signs suggest improving trends in the market? - Management noted a slight increase in procedures and sales in consumables, along with declining interest rates as positive indicators [17] Question: Can you provide updates on strategic alternatives? - The board is considering several strategic alternatives and has engaged Bank of America for assistance, with management not directly involved in the process [20] Question: What are the expectations for gross margins and EBIT margins? - Management indicated that new product launches, particularly lasers, may impact gross margins, and guidance is conservative based on past experiences [27][28] Question: How is the ApexRF platform performing? - The ApexRF platform is being sold alongside other products without a specialized sales team, and management is awaiting FDA indications before pushing it further [72] Question: What is the contribution of new product launches for 2026? - Two new products are expected to be launched in 2026, with significant marketing efforts planned, although specific financial contributions are not yet provided [41]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.9 million, up from $97.9 million in Q4 2024, while full-year revenue totaled $370.5 million, a 6% decrease compared to 2024 [8][9] - Gross margins for Q4 2025 were 78% on a GAAP basis, down from 79% in Q4 2024, while non-GAAP gross margins were 79% for both Q4 and full year 2025 [9][11] - GAAP diluted earnings per share for Q4 were $0.42, compared to $1.14 in Q4 2024, and $1.43 for the full year 2025, down from $2.25 in 2024 [11][12] Business Line Data and Key Metrics Changes - Revenue from consumables and services increased slightly compared to last year, indicating early signs of stabilization in patient activity [4] - Minimally invasive technology platforms accounted for 76% of total revenues in Q4 2025, while consumables and services represented 22% of revenue, up from 20% in 2024 [9][10] Market Data and Key Metrics Changes - Sales outside the U.S. totaled $48.5 million in Q4 2025, representing 47% of total sales and a 38% increase compared to Q4 2024, driven primarily by Europe [9] - For the full year 2025, sales outside the U.S. accounted for $171.8 million, or 46% of total sales, a 15% increase compared to 2024 [9] Company Strategy and Development Direction - The company views 2026 as a stabilization year following a prolonged period of industry softness, with expectations for revenue to be broadly in line with 2025 [4][7] - Product innovation is a key pillar of the strategy, with plans to launch two new platforms in 2026, including a Korean-made Pico laser device and a device combining new Morpheus technology with Erbium YAG laser [6][7] - The sales force is now segmented across aesthetic and wellness, with a dedicated team for specific platforms to drive increased penetration and improve sales productivity [5] Management's Comments on Operating Environment and Future Outlook - Management noted that the industry has not yet fully recovered from the global economic slowdown, with demand in North America remaining below historical levels, but there are early signs of stabilization in the U.S. and gradual improvement in Europe [7] - The CEO mentioned that interest rates starting to come down could positively impact leasing packages for capital equipment purchases, which may encourage more sales [16] Other Important Information - The company returned $127.4 million to shareholders through a disciplined share repurchase program [12] - The board of directors is exploring strategic alternatives to improve company value, having engaged Bank of America for assistance [19] Q&A Session Summary Question: What signs suggest improving trends in the market? - Management noted a slight increase in procedures and sales in consumables, along with declining interest rates as positive indicators [16] Question: Can you provide updates on strategic alternatives? - The board is considering several strategic alternatives to enhance company value, with management not directly involved in the process [19] Question: What are the expectations for gross margins and EBIT margins? - Management indicated that new product launches, particularly lasers, may impact gross margins, and guidance is conservative based on past experiences [27][28] Question: How significant is the laser market for future growth? - The CEO emphasized that laser platforms are essential for growth, despite being in a saturated market with lower margins compared to existing products [31][32] Question: What is the status of the dry eye indication and FDA approval timelines? - The company is working on FDA approval for a bipolar RF device for dry eye treatment, with studies expected to last through 2026 and possibly into 2027 [64][65]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.9 million, up from $97.9 million in Q4 2024, while full-year revenue for 2025 totaled $370.5 million, a 6% decrease compared to 2024 [7][8] - Gross margins in Q4 2025 were 78% on a GAAP basis, down from 79% in Q4 2024, while Non-GAAP gross margins remained at 79% for both Q4 and full year 2025 [8][10] - GAAP diluted earnings per share for Q4 were $0.42, compared to $1.14 in Q4 2024, and $1.43 for the full year 2025, down from $2.25 in 2024 [10][11] Business Line Data and Key Metrics Changes - Revenue from consumables and services increased slightly compared to last year, indicating early signs of stabilization in patient activity [4] - Minimally invasive technology platforms accounted for 76% of total revenues in Q4 2025, while consumables and services represented 22% of revenue, up from 20% in 2024 [8] Market Data and Key Metrics Changes - Sales outside the U.S. totaled $48.5 million in Q4 2025, representing 47% of total sales and a 38% increase compared to Q4 2024, driven primarily by Europe [8] - For the full year 2025, international sales accounted for $171.8 million, or 46% of total sales, reflecting a 15% increase compared to 2024 [8] Company Strategy and Development Direction - The company views 2026 as a stabilization year following a prolonged period of industry softness, with a focus on disciplined execution of its product roadmap and maintaining leadership in the aesthetic industry [4][6] - Product innovation remains a key pillar, with plans to launch two new platforms in 2026, including a Korean-made Pico laser device and a device combining new Morpheus technology with Erbium YAG laser [5][6] Management's Comments on Operating Environment and Future Outlook - Management noted that early signs of stabilization in the U.S. market and gradual improvement in Europe could support future performance [6] - The company is encouraged by a slight increase in procedures and sales in consumables, indicating potential recovery in the aesthetic space [16] Other Important Information - The company has returned $127.4 million to shareholders through a disciplined share repurchase program [11] - The board is exploring strategic alternatives to enhance company value, including hiring Bank of America for assistance [19] Q&A Session Summary Question: What signs suggest improving trends in the market? - Management noted declining interest rates and a slight increase in procedures and consumables sales as early signs of improvement [16] Question: Can you provide updates on strategic alternatives? - The board is considering several strategic alternatives to improve company value, with no direct involvement from management in the process [19] Question: What are the expectations for gross margins and EBIT margins? - Management indicated that new product launches, particularly lasers, may impact gross margins, which are expected to be in the neighborhood of 75% [29] Question: How is the ApexRF platform performing? - The ApexRF platform is being sold alongside other products without a specialized sales team, and management is awaiting FDA indications before pushing it further [73] Question: What is the outlook for international revenue? - Management expressed optimism about increasing direct sales in new subsidiaries, but could not definitively state if international revenue would surpass North America [58]

SAFE HARBOR DISCLAIMER • This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predi ...

Product Development and Innovation - The company introduced two new products, Luxora and ApexRF, in 2025, expanding its product offerings to a total of fourteen platforms[33]. - The company aims to enhance customer offerings through continuous innovation and the introduction of new product platforms to meet evolving consumer demands[180]. - The company is developing new RF energy-based platforms and handpieces for various medical specialties, including treatments for snoring and muscle spasms[181][184]. - The company has developed a proprietary technology for simultaneous fat destruction and skin tightening, believed to be the first RF-based, non-invasive body contouring technology that permanently destroys adipose tissue[196]. - The company offers a dual wavelength product for permanent hair reduction, Triton, which combines two wavelengths in one platform, claiming to be the only FDA-cleared, single-pulse, dual wavelength product for this purpose[201]. - The company plans to introduce the ApexRF and Solaria platforms in 2025, focusing on improved blood circulation and facial rejuvenation, respectively[207]. Market and Sales Strategy - The company relies heavily on sales professionals to market and sell its products globally, emphasizing the need for effective hiring, training, and retention strategies to maintain revenue growth[41]. - The company aims to expand its customer base to include new medical professionals such as ENTs and ophthalmologists, in addition to its existing customer segments[35]. - International sales accounted for approximately 46% of total revenue for the year ended December 31, 2025, indicating a significant reliance on global markets[63]. - The company plans to expand its direct sales presence in the United States and Canada, and establish sales and marketing organizations in Europe and Latin America[204]. - The company is focused on increasing its sales presence globally to broaden the adoption of its products and drive further market penetration[204]. Financial Performance and Risks - Revenue decreased to approximately $370.5 million for the year ended December 31, 2025, down from $394.8 million in 2024 and $492.0 million in 2023, with a gross margin of approximately 79%[185]. - The company recorded net income of approximately $93.9 million for 2025, down from $181.3 million in 2024 and $197.9 million in 2023[185]. - The company’s financial results may fluctuate due to various factors, including operational and financial system implementations and compliance with regulatory requirements[49]. - Economic uncertainty may reduce customer demand for the company's products, particularly in the aesthetic procedures market, impacting sales and financial condition[91]. - The company faces significant risks including market acceptance of its products, reliance on a limited number of suppliers, and potential product liability claims that could adversely affect financial results[32][51][45]. Regulatory Compliance and Legal Risks - The company is subject to extensive regulatory compliance obligations, particularly from the FDA, which could harm commercial operations if not maintained[124]. - The company must ensure that promotional materials comply with FDA regulations to avoid enforcement actions, which could damage reputation and sales[135]. - The company may face significant civil, criminal, and administrative penalties if found in violation of applicable laws, which could adversely affect its operations[104]. - The company is required to report adverse medical events to the FDA, and failure to do so could result in sanctions that harm its reputation and financial condition[143]. - The company may need to defend against litigation claiming infringement of intellectual property rights, which could divert resources and negatively impact its business[116]. Competition and Market Landscape - The competitive landscape in the medical aesthetics market is characterized by rapid technological advancements, necessitating continuous innovation from the company to remain competitive[52]. - The company faces intense competition from both public and private companies, which could lead to reduced prices and profit margins[55]. - The introduction of disruptive technologies in the medical technology industry poses a threat to the company's market position and product relevance[59]. Supply Chain and Operational Risks - The company outsources nearly all manufacturing to subcontractors, which may lead to delivery issues if operations are interrupted[75]. - The company relies on a limited number of suppliers for key components, making it vulnerable to supply shortages and price fluctuations, which could adversely affect revenue and profitability[80]. - Disruptions in the supply chain due to natural disasters or other extraordinary events could impair the company's ability to fulfill customer orders[84]. - The ongoing Israel-Hamas war and regional instability could impede the company's operations and negatively impact financial results[32][51]. Intellectual Property and Technology - The company’s ability to protect its proprietary technology is critical for maintaining its competitive position in the market[107]. - The company has issued 15 U.S. patents and one Korean patent, with 11 pending patent applications in the U.S. related to its technology and products[109]. - Intellectual property rights may not adequately protect the company’s competitive advantage, as competitors could develop similar technologies[122]. Management and Corporate Governance - The company has a strong management team with an average of over 16 years of experience in the medical aesthetics industry[203]. - The company is classified as a "foreign private issuer," which allows it to follow less stringent reporting obligations compared to U.S. domestic issuers, including not being required to issue quarterly reports[161]. - If the company loses its foreign private issuer status, it would face significantly higher regulatory and compliance costs under U.S. securities laws, requiring more detailed periodic reports[162].

Exhibit 99.1 InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million YOKNEAM, Israel, February 10, 2026 - InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year of 2025. ● Quarterly GAAP revenues of $103.9 million, compared to $97.9 million in the fourth quarter of 2024. ● Quarterly r ...

YOKNEAM, Israel, Feb. 2, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies ("InMode" or the "Company"), today issued the following statement: The Company is aware of recent market speculation and rumors, including reports relating to the publicly announced non-binding proposal by Steel Partners Holdings L.P. to acquire 51% of the Company's outstanding shares and recent statements attributed to the Company's Chief Executive Officer. Without derogat ...